Temporary Occlusion and Therapeutic Delivery System
Legal Citation
Summary of the Inventive Concept
A novel embolic particle system for temporary occlusion of vascular defects, incorporating biodegradable materials, controlled release of therapeutic agents, and advanced delivery mechanisms to promote tissue healing and reduce inflammation.
Background and Problem Solved
The original patent describes embolic particles with a first diameter for delivery through a microcatheter and a second expanded diameter for occluding vascular defects. However, these particles may cause permanent occlusion, leading to potential complications. The new inventive concept addresses this limitation by introducing temporary occlusion and therapeutic delivery capabilities.
Detailed Description of the Inventive Concept
The system comprises embolic particles made of biodegradable materials that dissolve after a predetermined time period, allowing for temporary occlusion of vascular defects. The particles can be infused with therapeutic agents, which are released in a controlled manner to promote tissue healing and reduce inflammation. The system also includes advanced delivery mechanisms, such as a microcatheter with a specialized tip for precise navigation through tortuous vessels and a flow diverting stent to trap the embolic particles.
Novelty and Inventive Step
The new claims introduce the concept of temporary occlusion using biodegradable materials, controlled release of therapeutic agents, and advanced delivery mechanisms, which are not present in the original patent. These features provide a significant improvement over the existing technology.
Alternative Embodiments and Variations
Alternative embodiments may include different biodegradable materials, varying particle sizes, or different therapeutic agents. Additionally, the system could be adapted for use in other luminal defects, such as those in the bile ducts, urethra, or vagina.
Potential Commercial Applications and Market
The temporary occlusion and therapeutic delivery system has significant commercial potential in the medical device industry, particularly in the fields of interventional radiology and cardiology. The system's ability to promote tissue healing and reduce inflammation could lead to improved patient outcomes and reduced healthcare costs.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61L24/06 |
| A | A61 | A61L24/001 |
| C | C08 | C08F222/385 |
| A | A61 | A61L2430/36 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Medical device engineering, specifically interventional radiology and embolic particle design for vascular occlusion, requiring expertise in polymer chemistry, medical device materials, and minimally invasive therapeutic techniques
Person of Ordinary Skill (PHOSITA) Profile
A biomedical engineer or medical device researcher with advanced degrees in materials science or bioengineering, experienced in designing polymeric medical implants, familiar with microcatheter delivery systems and vascular intervention techniques
Obviousness Rationale
A PHOSITA would recognize that the PTD's variations represent predictable extensions of the source patent's core embolic particle technology by introducing well-known biomedical engineering techniques such as controlled degradation, therapeutic agent incorporation, and advanced delivery mechanisms. The fundamental concept of expandable embolic particles remains consistent, with the PTD merely adding standard biomedical design improvements that would be obvious to implement. The modifications represent incremental advances using known methodologies within the established technological framework of vascular occlusion devices.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,694 |
|---|---|
| Title | Particles |
| Assignee(s) | MicroVention, Inc. |